Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-01 in Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT05475925Phase 2Recruiting
- Sponsor
- Dren Bio
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 9
01
Overview
Phase 2, open-label trial of DR-01 in large granular lymphocytic leukemia (LGLL) (7 arms), sponsored by Dren Bio. Primary endpoints: Incidence and severity of adverse events at 25 months, Incidence and severity of dose limiting toxicities at 28 days and 2 more. Started Jul 2022; status: recruiting.
02
Drugs
DR-01
03
Conditions
large granular lymphocytic leukemia (LGLL)
Beyond the preview
Go deeper on NCT05475925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05475925.